Int J Stomatol

Inter J Stomatol ›› 2017, Vol. 44 ›› Issue (1): 83-86.doi: 10.7518/gjkq.2017.01.017

• ·Reviews· • Previous Articles     Next Articles

Chemotherapy in the treatment of osteosarcoma in oral maxillofacial-head and neck region

Li Xiao, Ji Tong.   

  1. Dept. of Oral and Maxillofacial-Head and Neck Tumor, The Ninth People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Key Laboratory of Stomatology, Shanghai 200011, China
  • Received:2016-02-06 Online:2017-01-01 Published:2017-01-01

RichHTML

4

PDF (PC)

506

Abstract: Osteosarcoma is one of the rare malignant tumors in the maxillofacial region. Synthetic sequential therapy including radical resection and adjuvant radio-chemotherapy is the most effective currently. Chemotherapy is an important part in synthetic sequential therapy. In the existing chemotherapy regimens, traditional chemotherapy such as MAP(methotrexate, adriacin, cisplatin) plays a key role in the treatment of osteosarcoma in oral maxillofacial-head and neck region. In addition, some other regimens such as neoadjuvant chemotherapy, electrochemical therapy are also proposed in recent years, but their effectiveness remains to be investigated. Chemotherapy has a significant effect on improving the prognosis of osteosarcoma. With the gradual development of the cognition of osteosarcoma molecular biology in recent years, it has become a new trend to study the chemical drugs for tumor cells in the level of molecular biology. This paper reviews the application of chemotherapy in the treatment of osteosarcoma in oral and maxillofacial- head and neck region.

Key words: osteosarcoma, chemotherapy, oral and maxillofacial region

CLC Number: 

  • R739.82

TrendMD: 
[1] 郭伟. 头颈肿瘤诊断治疗学[M]. 北京: 人民军医出版社, 2013:196-207. Guo W. Diagnosis and treatment of head and neck cancer[M]. Beijing: People’s Military Medical Press, 2013:196-207.
[2] Taghavi N, Mehrdad L, Rajabi M, et al. A 10-year retrospective study on malignant jaw tumors in Iran [J]. J Craniofac Surg, 2010, 21(6):1816-1819.
[3] van den Berg H, Merks JH. Incidence and grading of cranio-facial osteosarcomas[J]. Int J Oral Maxillofac Surg, 2014, 43(1):7-12.
[4] Wang S, Shi H, Yu Q. Osteosarcoma of the jaws: demographic and CT imaging features[J]. Dentoma-xillofac Radiol, 2012, 41(1):37-42.
[5] Kämmerer PW, Shabazfar N, Vorkhshori Makoie N, et al. Clinical, therapeutic and prognostic features of osteosarcoma of the jaws-experience of 36 cases[J]. J Craniomaxillofac Surg, 2012, 40(6):541-548.
[6] Argon A, Doğanavşargıl B, Ünal Yıldırım F, et al. Osteosarcomas of jaw: experience of a single centre [J]. J Plast Surg Hand Surg, 2015, 49(1):13-18.
[7] Mücke T, Mitchell DA, Tannapfel A, et al. Effect of neoadjuvant treatment in the management of osteo-sarcomas of the head and neck[J]. J Cancer Res Clin Oncol, 2014, 140(1):127-131.
[8] Miwa S, Takeuchi A, Shirai T, et al. Prognostic value of radiological response to chemotherapy in patients with osteosarcoma[J]. PLoS One, 2013, 8(7):e70015.
[9] Sakamoto A, Iwamoto Y. Current status and perspec-tives regarding the treatment of osteosarcoma: chemotherapy[J]. Rev Recent Clin Trials, 2008, 3(3): 228-231.
[10] Gill J, Ahluwalia MK, Geller D, et al. New targets and approaches in osteosarcoma[J]. Pharmacol Ther, 2013, 137(1):89-99.
[11] Meyers PA, Schwartz CL, Krailo MD, et al. Osteo-sarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children’s Oncology Group[J]. J Clin Oncol, 2008, 26(4):633-638.
[12] Chou AJ, Kleinerman ES, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group[J]. Cancer, 2009, 115(22):5339-5348.
[13] Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century[J]. J Clin Oncol, 2010, 28(15):2625-2634.
[14] Anninga JK, Gelderblom H, Fiocco M, et al. Chemo-therapeutic adjuvant treatment for osteosarcoma: where do we stand[J]. Eur J Cancer, 2011, 47(16): 2431-2445.
[15] Daw NC, Neel MD, Rao BN, et al. Frontline treat-ment of localized osteosarcoma without methotrexate [J]. Cancer, 2011, 117(12):2770-2778.
[16] 邱蔚六, 郑家伟. 应重视口腔颌面部恶性肿瘤的综合序列治疗[J]. 中国口腔颌面外科杂志, 2005, 3 (3):179-182. Qiu WL, Zheng JW. Comprehensive and sequential therapy for oral and maxillofacial malignancies: an evolving concept and clinical significance[J]. Chin J Oral Maxillofac Surg, 2005, 3(3):179-182.
[17] Granowski-LeCornu M, Chuang SK, Kaban LB, et al. Osteosarcoma of the jaws: factors influencing prognosis[J]. J Oral Maxillofac Surg, 2011, 69(9): 2368-2375.
[18] Thariat J, Julieron M, Brouchet A, et al. Osteosar-comas of the mandible: are they different from other tumor sites[J]. Crit Rev Oncol Hematol, 2012, 82(3): 280-295.
[19] Thariat J, Schouman T, Brouchet A, et al. Osteosar-comas of the mandible: multidisciplinary manage-ment of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE[J]. Ann Oncol, 2013, 24(3):824-831.
[20] Mali B, Jarm T, Snoj M, et al. Antitumor effective-ness of electrochemotherapy: a systematic review and meta-analysis[J]. Eur J Surg Oncol, 2013, 39(1): 4-16.
[21] Campana LG, Bertino G, Rossi CR, et al. The value of electrochemotherapy in the treatment of peristomal tumors[J]. Eur J Surg Oncol, 2014, 40(3):260-262.
[22] Isobe K, Shimizu T, Nikaido T, et al. Low-voltage electrochemotherapy with low-dose methotrexate enhances survival in mice with osteosarcoma[J]. Clin Orthop Relat Res, 2004(426):226-231.
[23] Mücke T, Mitchell DA, Tannapfel A, et al. Outcome in adult patients with head and neck sarcomas—a 10-year analysis[J]. J Surg Oncol, 2010, 102(2):170- 174.
[24] Mendenhall WM, Fernandes R, Werning JW, et al. Head and neck osteosarcoma[J]. Am J Otolaryngol, 2011, 32(6):597-600.
[25] 李江, 何荣根. 颌面部骨肉瘤61例临床病理研究[J]. 中华口腔医学杂志, 2003, 38(6):444-446. Li J, He RG. Osteosarcoma of maxillofacial area: a clinicopathological study of 61 cases[J]. Chin J Stomatol , 2003, 38(6):444-446.
[26] Smith RB, Apostolakis LW, Karnell LH, et al. Na-tional Cancer Data Base report on osteosarcoma of the head and neck[J]. Cancer, 2003, 98(8):1670- 1680.
[27] Whelan J, McTiernan A, Cooper N, et al. Incidence and survival of malignant bone sarcomas in England 1979—2007[J]. Int J Cancer, 2012, 131(4):E508- E517.
[28] Junior AT, de Abreu Alves F, Pinto CA, et al. Clini-copathological and immunohistochemical analysis of twenty-five head and neck osteosarcomas[J]. Oral Oncol, 2003, 39(5):521-530.
[29] Eid A, Li S, Garza R, et al. Chemotherapy for oral and maxillofacial tumors: an update[J]. Oral Maxi-llofac Surg Clin North Am, 2014, 26(2):163-169.
[30] Luetke A, Meyers PA, Lewis I, et al. Osteosarcoma treatment-where do we stand? A state of the art review[J]. Cancer Treat Rev, 2014, 40(4):523-532.
[31] Kuba K, Inoue H, Hayashi T, et al. Laryngeal osteo-sarcoma: case report and literature review[J]. Head Neck, 2015, 37(2):E26-E29.
[32] Beckingsale TB, Gerrand CH. Osteosarcoma[J]. Orthopaed Trauma, 2010, 24(5):321-331.
[33] Park HR, Cabrini RL, Araujo ES, et al. Expression of ezrin and metastatic tumor antigen in osteo-sarcomas of the jaw[J]. Tumori, 2009, 95(1):81-86.
（本文采编 王晴）
[1] Yang Mingyan,Zhang Fan,Zhao Lei. Research progress on oral flora changes affecting the course of radiotherapy and chemotherapy-related oral mucositis [J]. Int J Stomatol, 2023, 50(1): 43-51.
[2] She Yangyang, Nong Xiaolin.. Clinical application of botulinum toxin type A in oral and maxillofacial region [J]. Inter J Stomatol, 2017, 44(6): 707-711.
[3] Guo Wenhao, You Meng, Luo Jingjing, Wang Kaili, Wang Hu, Zheng Guangning. Four cases of X-ray and cone beam computed tomography radiographic findings of non-Hodgkin’s lymphoma involving jaws in the oral and maxillofacial region [J]. Inter J Stomatol, 2016, 43(2): 146-150.
[4] Lü Danni, Li Ronglin, Yang Guangwei, Li Chunyang. Prevention and treatment of radiation- and chemotherapy-induced oral mucositis [J]. Inter J Stomatol, 2015, 42(2): 177-180.
[5] Gu Qianping, Meng Jian, Meng Qingfei, Zhang Jie, Li Zhiping.. Clinical study on Nimotuzumab combined with Docetaxel-Cisplatin-Fluorouracil regimen in the treatment of advanced oral carcinoma [J]. Inter J Stomatol, 2011, 38(6): 652-655.
[6] ZHANG Jinge, TANG Wei, ZHANG Ping.. Clinical application on administration routes in the chemotherapy of head and neck cancer [J]. Inter J Stomatol, 2011, 38(2): 210-213.
[7] CHENG Shi-bing, XIE Hui-xu, LI Long-jiang.. Research progress of clinical application of thermochemotherapy of tumor [J]. Inter J Stomatol, 2010, 37(3): 337-337～340.
[8] XIA Yong, NONG Xiao-lin. Advances in treatment of salivary gland malignant tumor [J]. Inter J Stomatol, 2009, 36(1): 46-46～49.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[2] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[3] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[4] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[5] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[6] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[7] . [J]. Foreign Med Sci: Stomatol, 2005, 32(06): 458 -460 .
[8] . [J]. Foreign Med Sci: Stomatol, 2005, 32(06): 452 -454 .
[9] . [J]. Inter J Stomatol, 2008, 35(S1): .
[10] . [J]. Inter J Stomatol, 2008, 35(S1): .